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Anti-emetic guidelinesAbstract Purpose: Chemotherapy is the mainstay of cancer treatment; however, chemotherapy
treatment may cause nausea and vomiting, which could cause 25–50% of patients to consider delay-
ing or refusing further cancer treatment. Chemotherapy-induced nausea and vomiting (CINV), can
be prevented in 70–80% of patients with evidence-based anti-emetic regimen. The purpose of this
study is to assess prescribing patterns with regard to prevention of CINV, in the national center
for cancer care and research (NCCCR), and develop and implement a standardized evidence-based
guideline for the management of CINV. Methods: 25 anti-emetic prescriptions were audited to
assess their conformity with either of the published guidelines; Multinational Association of Sup-
portive Care in Cancer (MASCC), American Society of Clinical Oncology (ASCO), or the National
Comprehensive Cancer Network (NCCN), to establish baseline data. A multidisciplinary team of
clinical pharmacists and oncologists developed and implemented a guideline for the prevention
of CINV. The guideline was promoted using a variety of strategies; education, pocket cards, aca-
demic detailing and pharmacist intervention. Physician anti-emetic orders were audited by pharma-
cists, to assess their conformity with NCCCR anti-emetic guidelines. A data collection form was
developed to capture relevant information including; patient demographics, type and emetogenic
level of chemotherapy, and the conformity of anti-emetic order with NCCCR guidelines. SPSS sta-
tistical software was used to analyze the data. Results: The conformity of anti-emetic physician
order with NCCCR anti-emetic guidelines increased from 0% baseline in June 2008 to an average
382 M. Zaidan et al.of 60.006% (n= 331) by December 2010 and consistently increased reaching 94.3827% (n= 792)
by December 2013, (p value 0.0002). Conclusion: The introduction of anti-emetic guidelines suc-
ceeded in standardizing CINV management, toward an evidence-based approach.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chemotherapy is the mainstay of treatment for many cancers;
however, chemotherapy treatment could cause many
unwanted side effects among which nausea and vomiting are
the most feared by patients. Chemotherapy-induced nausea
and vomiting (CINV) are classiﬁed into three classes according
to the pattern and time in which it occurs; acute which occurs
within 24 h of chemotherapy, delayed occurs after 24 h of che-
motherapy, and anticipatory nausea and vomiting (Naeim
et al., 2008; Wiser and Berger, 2005). As many as 70–80% of
all patients treated, experience nausea and vomiting of varying
severity (Berger and Clark-Snow, 2004). Nausea and vomiting,
can lead to dehydration, fatigue, difﬁculty concentrating, slow
wound healing, loss of appetite, as well as distress and disrup-
tion in daily activities which may cause 25–50% of patients to
consider delaying or refusing possible lifesaving further cancer
treatment (Jordan et al., 2007a; Naeim et al., 2008).
Yet considerable progress has been made in the treatment
of CINV in patients receiving standard doses of chemotherapy
following the introduction of newer drugs; 5-hydroxytripta-
mine-3 antagonist (5-HT3) antagonists, and neurokinin
1 (NK(1)) antagonists i.e. Aprepitant, which are more
effective in controlling and even preventing nausea and vomit-
ing (http://www.cancer.gov/cancertopics/pdq/supportivecare/
nausea/HealthProfessional/page 6 Accessed June 2008, Poli-
Bigelli et al., 2003; Richard et al., 1999; Kaiser, 2005). In fact,
CINV can be prevented in 70–80% of patients with the appro-
priate use of anti-emetics (Jordan et al., 2007a; Perwitasari
et al., 2011). Meaning that 20–30% of the patients will still suf-
fer CINV despite being prescribed the appropriate anti-emetic
regimen according to the guidelines (Jordan et al., 2007b;
Kaiser, 2005).
Guidelines for the management of CINV that integrate
clinical research into practices have been developed by reputa-
ble institutions including; the Multinational Association of
Supportive Care in Cancer (MASCC), (http://www.mascc.
org/antiemetic-guidelines, accessed June 2008), American Soci-
ety of Clinical Oncology (ASCO), (Basch et al., 2011), and
National Comprehensive Cancer Network (NCCN) (http://
www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf,
accessed June, 2008). These guidelines categorize chemothera-
peutic agents into four categories according to their likelihood
to induce nausea and vomiting; high (90%), moderate (30–
90%), low (10–30%), and minimal (<10%). These ﬁgures rep-
resent the percentage of patients who would experience CINV
if not prescribed appropriate prophylaxis. The guidelines fur-
ther suggest anti-emetic regimens that would provide the best
control of all types of nausea and vomiting; acute, delayed
and anticipatory putting into consideration the likelihood of
the chemotherapeutic agent to cause nausea and vomiting
(Roila et al., 1998; Frederick, 2003; Jordan et al., 2007b)
however, the implementation of these guidelines is less thanoptimal for a variety of reasons including, disagreement with
the guidelines due to concerns about the underlying evidence,
lack of knowledge and unclear guidelines (Jordan et al.,
2007a; Lugtenberg et al., 2009). Physician adherence to guide-
lines may also vary according to type of patient and length of
physician experience (Mackinlay et al., 2007). Some studies
show that as low as 50% of patients receive according to
recommended guidelines (McGlynn et al., 2003); however,
‘‘greater adherence to evidence-based guidelines is critical to
improving healthcare’’ (Keneﬁck et al., 2008).
Expert panels have identiﬁed major barriers to physician
adherence as; ‘‘physicians rewarding systems that are based
on service volume (quantity) rather than quality of outcomes;
lack of information technology systems which would make it
easier to access guidelines; lack of staff training; the likeli-
hood of physicians to base clinical decisions on their per-
sonal experience, rather than evidence-based clinical
practice guidelines; physicians’ belief that their own practice
is good which could be attributed to lack of feedback about
the quality of their practice compared to their peers, and lack
of physician involvement in guideline development process
which would otherwise improve adherence’’ (Keneﬁck
et al., 2008).
The same article suggests several strategies to improve phy-
sician adherence; information technology innovations to
improve access to guidelines, support clinical decision-making,
involvement of physicians in guideline development and review
process; staff awareness and training to re-orient practice
toward guidelines and measurement of health care perfor-
mance (Keneﬁck et al., 2008).
An audit of 25 anti-emetic prescriptions conducted at the
National Center for Cancer Care and Research (NCCCR),
in May, June 2008, revealed considerable variation in individ-
ual physician’s approach toward management of CINV which
implies that, management of CINV is not standardized and is
mostly guided by individual physician opinion and experience,
which could lead to either suboptimal control of CINV, or
unnecessary over-treatment.
The primary purpose of this study is to assess the current
clinical practice in NCCCR with regard to the management
of CINV, in terms of the rate of physician orders conforming
to either of the published anti-emetic guidelines; MASCC,
ASCO, or NCCN, and develop and promote a standardized
evidence-based guideline for the management of CINV in
NCCCR.
2. Materials and methods
This quality improvement project was conducted in the
national center for cancer care and research, Doha, Qatar, in
the period July 2008 to December 2013. The project was con-
ducted with the permission of the Medical Research Center at
Hamad Medical Corporation (PR # 14353/14).
Figure A1 NCCCR anti-emetic guidelines for chemotherapy induced nausea and vomiting.
Table 1 Percentage physician order conformance to NCCCR anti-emetic guidelines 2nd Quarter 2008–4th Quarter 2013.
Year Quarter Number of. Ph. O.
audited guidelines
Number of Ph. O. conformant
to NCCCR antiemetic guidelines
% Ph. O. conformant
to NCCCR antiemetic guidelines
% Yearly Ph. O. conformant
to NCCCR antiemetic
2008 3rd Q 66 7 10.6 18.64
4th Q 45 12 26.67
2009 1st Q 53 24 45.28 65.34
2nd Q 53 39 73.58
3rd Q 53 34 64.15
4th Q 60 47 78.33
2010 1st Q 50 40 80 75.36
2nd Q 50 36 72
3rd Q 60 43 71.67
4th Q 63 49 77.78
2011 1st Q 56 48 85.71 91.72
2nd Q 44 42 95.45
3rd Q 66 59 89.39
4th Q 82 79 96.37
2012 1st Q 68 64 94.12 94.57
2nd Q 80 78 97.5
3rd Q 62 58 93.55
4th Q 58 54 93.1
2013 1st Q 52 51 98.08 96.71
2nd Q 44 44 100
3rd Q 99 94 94.94
4th Q 129 121 93.8
Q = Quarter
Ph. O. = Physician order
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audited in June 2008 to assess their conformity with either of
the published guidelines; Multinational Association of Sup-
portive Care in Cancer (MASCC), American Society of Clini-
cal Oncology (ASCO), or the National Comprehensive Cancer
Network (NCCN). The rate of physician adherence to these
guidelines was found to be 0%.
A multidisciplinary team of oncologists and pharmacists,
reviewed NCCN, ASCO, and MASCC antiemetic guidelines,
and developed and implemented a customized antiemetic
guideline based on available evidence as well as availability
of the required medications in the hospital formulary with
the objective of achieving the best possible control of CINV
(Figs. A1–A3). The guideline was promoted among care pro-
viders using a variety of strategies to overcome potential bar-
riers to physician adherence to the guidelines; educational
sessions, interactive workshops, posting laminated copies of
the guidelines and reminders in nurse stations, treatment
rooms and pharmacy work areas, distribution of pocket size
copies of the guideline to all physicians and pharmacists in
addition to academic detailing to provide objective clinical
knowledge to individual physicians to improve their confor-
mance to the guidelines (Fischer and Avorn, 2012). Pharma-
cists were instructed to communicate with prescribers toFigure A2 Emetogenic risk of indicorrect any variation from the guidelines before dispensing
and document their interventions. The guideline and the data
collection process were piloted for one month and eventually
launched in July 2008.
Actions
All anti-emetic regimens prescribed for oncology patients
receiving ﬁrst cycle of chemotherapy in the day-care unit
(DCU) were audited by dispensing pharmacists for conformity
with NCCCR anti-emetic guidelines. A specially designed data
collection form was made available in all pharmacy work areas
to be ﬁlled by dispensing pharmacists (Fig. B1). Collected
information included; patient demographics, Diagnosis, Name
and emetogenic level of the chemotherapy protocol, anti-eme-
tic medications prescribed, and conformity of the prescribed
anti-emetic regimen with NCCCR anti-emetic guidelines.
2.1. Inclusion criteria
All anti-emetic regimens prescribed for oncology patients
receiving ﬁrst cycle of chemotherapy in the day-care unit
(DCU).vidual chemotherapeutic agents.
Figure A3 Emetogenic risk of combination chemotherapy.
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Patients receiving chemotherapy in medical wards.3. Results
The rate of conformity of anti-emetic physician orders to
NCCCR anti-emetic guidelines following the implementation
of NCCCR anti-emetic guidelines, increased from an average
of 60.006% (n= 331) in the period July 2008–December
2010 to 94.3827% (n= 792) in the period January 2011–
December 2013, (p value 0.0002) Table 1, Fig. C1.Figure B1 Data collection form.4. Discussion
The rate of conformity of anti-emetic physician orders to
NCCCR antiemetic guidelines showed a slow but consistent
improvement at the beginning, taking as long as 18 months
to reach the initial 75% target. This could be attributed to
the fact that the project involved a change in physician mindset
and prescribing habits. However, the rate of anti-emetic order
conformity with the guidelines, showed a consistent improve-
ment exceeding the initial target. Consequently the target
was raised to 90% in January 2011, and again to 100% in Jan-
uary 2012 as the rate of conformity to the guidelines improved
exceeding the 90% target. The multidisciplinary approach,
periodic education, pocket cards, introduction of novel drugs
(Aprepitant), and pharmacist intervention were the major suc-
cess factors. The hospital management adopted physician
adherence to the anti-emetic guidelines as a patient safety indi-
cator which provided an excellent chance to keep the imple-
mentation efforts as a standing agenda to be discussed in the
monthly hospital quality improvement and patient safety com-
mittee (QIPS) meetings. The audit results, intervention strate-
gies, and speciﬁc action plan to improve physician order
conformance to the guidelines were periodically discussed with
prescribers during the regular physician morning report meet-
ings. To further ensure that patients receive adequate antieme-
sis therapy, the guideline has been incorporated into pre-
printed chemotherapy protocols which considerably contrib-
uted to the maintenance of the current rate of conformance
(94.3%), since January 2011.
The guideline is a proactive approach to the prevention of
CINV, providing speciﬁc drug recommendations for the man-
agement of acute, delayed as well as anticipatory nausea and
vomiting to achieve maximum control of CINV without undueover or under-use of hospital resources. It has been developed
based on medications available on the hospital formulary;
however, the study team stays vigilant to new advancements
in the management of CINV. In due course, Aprepitant-P/neu-
rokinin 1 (NK1) receptor antagonist was added to the formu-
lary in April 2009 and the guideline was updated accordingly.
To improve patient accessibility to required medications, all
chemotherapy pre-medications used to prevent acute and
anticipatory CINV are provided free of charge to all patients
as an integral part of the chemotherapy protocol.
The guideline also emphasizes an evidence based clinical
decision making approach rather than personal opinion guided
practice and would encourage other healthcare entities to
develop clinical practice guidelines to optimize drug therapy.
As evidenced by multiple studies consistent implementation
of the guidelines reduces the incidence and severity of CINV
improving thus, patient adherence to chemotherapy, reduce
Figure C1 % Ph. O. conformance to NCCCR guidelines 2008–
2013.
386 M. Zaidan et al.treatment delays and improve clinical outcomes; however, fur-
ther study is required to assess the impact of consistent confor-
mance with antiemetic guidelines in NCCCR.
5. Conclusion
The introduction of the guidelines was an important shift
toward evidence-based practice, as evidenced by the implemen-
tation of the clinical practice guidelines for the management of
chemotherapy induced nausea and vomiting in NCCCR, and
although, the program involved a change inphysicians’ prescrib-
ing practices which is rather a slow process, the program suc-
ceeded in achieving its deﬁned goals. This could be attributed
to a ﬁrm and consistent support from hospital management as
well as consistent educational activities to promote the guide-
lines. Availability of new products speciﬁcally for the treatment
of CINV, which provide extra options for the prescribers and
improves physician conformance with guidelines, in addition
to active involvement of pharmacists to discuss variations from
prescribing guidelines were critical to improvement.
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